Purdue Frederick Company, Inc.

Purdue Frederick Company, Inc. was the company that pleaded guilty in the 2007 federal case over OxyContin’s marketing. Its story in the book turns on the distance between documented risks and public claims of ignorance, and on the narrowing of a case that prosecutors had once considered bringing against the company and its senior executives on a far broader set of felony charges.

Corporate identity and the OxyContin record

The company appears in the federal court record as the defendant in the plea agreement and agreed statement of facts. Those materials included falsified charts created by Purdue and documented that the drug’s abuse risks were known before the company later said it had become aware of the problem. The book cites the plea-agreement record as evidence of what prosecutors could establish, rather than treating the case as a general dispute over pharmaceutical policy.

The premarket record presented a particularly concrete challenge to Purdue’s account. The 1995 review of OxyContin’s application described how crushing the tablets could release the drug immediately instead of in a controlled manner, noted withdrawal symptoms among some clinical-trial patients, and reported that 68 percent of the oxycodone in a crushed pill could be recovered for injection. Purdue maintained that it did not know about the drug’s abuse problems until February 2000. The contrast between that claim and the earlier review is central to the book’s account of the company’s responsibility.

The regulatory history also complicates any simple division between company conduct and public oversight. Curtis Wright, the examiner who approved the drug, urged caution in its marketing materials; two years later, he would work as a consultant for Purdue Pharma. The book presents that later relationship alongside the documented warnings, without making it a substitute for the specific evidence contained in the application review.

A wider regulatory and industry setting

Purdue’s case sits within a broader account of the opioid industry’s influence on pain policy. A 2013 investigation by a Milwaukee Journal Sentinel reporter brought attention to private annual meetings between regulators and pharmaceutical executives, held through an industry-funded nonprofit from at least 2002. Those meetings led to the development of enriched enrollment, a method that could remove study participants who did not respond well to a drug, tilting the evidence base toward approval. The account does not establish that Purdue attended those meetings; it places them in the wider regulatory environment in which opioid products were assessed.

The same reporter documented that the American Pain Society and the American Academy of Pain Medicine advocated expanded opioid use for long-term chronic pain while receiving millions of dollars from drug companies. The resulting 2012 Senate investigation targeted the American Pain Foundation and Purdue, among other organizations and pharmaceutical companies. Its findings remained sealed in the Senate Finance Committee’s office, despite periodic calls for disclosure. Purdue’s place in this episode is therefore both specific and incomplete: it was among the investigation’s targets, but the public could not inspect the findings described in the book.

Investigation and plea negotiations

By the fall of 2006, federal prosecutors had assembled a case that Purdue’s lawyers understood to be different from an ordinary corporate dispute. The charges under consideration extended beyond misbranding to mail fraud, wire fraud, and money laundering, and prosecutors discussed indicting the company’s senior executives as well as the corporation. The potential scale of the financial penalty was also contested: Purdue initially offered $10 million, while the government’s initial proposal was $1 billion.

The negotiations were accompanied by efforts to influence the case. An observer connected to the prosecution said the case was watered down as it moved through United States Department of Justice headquarters, while Purdue representatives, including Rudy Giuliani, lobbied against felony indictments of the executives. Earlier, Purdue lawyers had raised concerns about John Brownlee’s investigative methods with then–Deputy Attorney General James Comey, who in turn questioned Brownlee. Brownlee drove to Washington to explain his strategy; Comey ultimately told him to return to Virginia and proceed with the case.

The pressure continued as the plea deadline approached. In October 2006, the night before the agreement was due to expire, a senior Justice Department officer called Brownlee at home, at the request of a Purdue lawyer, and urged him to extend the deadline. Brownlee refused. Purdue accepted the plea agreement later that night rather than risk more serious charges or a trial in western Virginia, where the drug’s problems had become widely known. Eight days afterward, Brownlee found his name on a list of five United States attorneys slated for dismissal. He was not ultimately fired, but the episode intensified criticism of Attorney General Alberto Gonzales and raised concerns about political interference in the work of prosecutors’ offices. The request for more time had been made by Mary Jo White, the defense lawyer for Howard Udell, one of Purdue’s senior executives.

Penalties and continuing consequences

The 2007 agreement produced a reported $634.5 million fine. Its listed payments included $276.1 million forfeited to the United States; $160 million to resolve false-claims liability involving Medicaid and other government health programs; $130 million for private civil claims; $5.3 million for the Virginia Attorney General’s Medicaid Fraud Control Unit; and $20 million for Virginia’s prescription monitoring program. The company was also to pay the maximum statutory criminal fine of $500,000. The distribution directed money toward government programs and claims as well as forfeiture, but the book’s account sets these financial consequences against the much larger penalties prosecutors had initially contemplated.

The three executives named in the case—Michael Friedman, Howard Udell, and Paul Goldenheim—were fined separately: $19 million, $8 million, and $7.5 million, respectively, with an additional $5,000 fine for each. Their exclusion from taxpayer-financed health programs was also contested. An initial twenty-year disbarment was reduced to twelve years, and Randy Ramseyer later said the executives were ultimately excluded for eight years. The Abingdon federal judge’s hands were tied, a constraint that the book presents as part of the limits of the outcome, not as evidence that the case had resolved the continuing public-health crisis.

Significance in the book

Purdue Frederick Company, Inc. represents a corporate defendant whose documented product risks, contested marketing, and federal plea can be followed through court records and the course of the prosecution. Yet the narrative refuses to equate a large settlement with a complete reckoning: prosecutors’ earlier proposals were substantially more severe, the Senate investigation’s findings remained sealed, and opioid addiction continued after the case. The company’s legal outcome thus sits beside the book’s account of the institutions meant to respond to the crisis—regulators, health care, and criminal justice—and the uneven consequences borne by people and families caught between them.